The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Lurbinectedin (PM01183) with doxorubicin (DOX), an active treatment as second-line therapy in small cell lung cancer (SCLC).
 
Martin Forster
Consulting or Advisory Role - Boston Biomedical; Lilly; PharmaMar
Travel, Accommodations, Expenses - Boston Biomedical; Lilly; MSD; Roche Pharma AG
 
Emiliano Calvo
Consulting or Advisory Role - Astellas Pharma; GlaxoSmithKline; Lilly/ImClone; Nanobiotix; Novartis; Pfizer; Roche/Genentech
Speakers' Bureau - Novartis
Research Funding - Abbvie; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; Janssen Oncology; Lilly; Merck; Millennium; Nektar; Novartis; OncoMed; Pfizer; PharmaMar; PsiOxus Therapeutics; Puma Biotechnology; Roche/Genentech; Sanofi; Spectrum Pharmaceuticals
Travel, Accommodations, Expenses - Lilly; Novartis; PsiOxus Therapeutics
 
Maria Eugenia Olmedo Garcia
No Relationships to Disclose
 
M. Pilar Lopez Criado
No Relationships to Disclose
 
Victor Moreno
No Relationships to Disclose
 
Arturo Soto-Matos
Employment - PharmaMar
Stock and Other Ownership Interests - PharmaMar
 
Esther Holgado
No Relationships to Disclose
 
Nicholas F. Brown
No Relationships to Disclose
 
Michael Flynn
Employment - MedImmune
Research Funding - MedImmune
 
Valentina Boni
No Relationships to Disclose
 
Eva Guerra Alia
No Relationships to Disclose
 
Sergio A. Szyldergemajn
Employment - Bristol-Myers Squibb (I); PharmaMar
Stock and Other Ownership Interests - Bristol-Myers Squibb (I); PharmaMar